Agentic Spatial Reality for trusted preclinical functional evidence
SWARMOSCOPE is a controlled zebrafish phenotyping and evidence platform designed to connect molecular, imaging and treatment signals with measurable whole-organism function, before selective mammalian validation.
One organism. Longitudinal identity. Controlled challenge. Multimodal evidence. Researcher-reviewed decisions.
One platform. Three therapeutic modules.
A shared evidence platform with three therapeutic solution modules. CNS is the current first validation wedge; Cardio and Oncology are expansion modules.
From molecular signal to functional evidence
Human-relevant cells, organoids, molecular and imaging signals
Discovery teams screen rapidly in cells, organoids, and imaging systems to identify promising candidates.
SWARMOSCOPE controlled zebrafish phenotyping
Measure whether a candidate creates a meaningful, repeatable, tolerated whole-organism functional response.
Selective mammalian validation
Focus costly mammalian studies on stronger candidates and better-defined follow-up questions.
SWARMOSCOPE complements, not replaces, human-relevant screening and mammalian validation.
The evidence gap from cells to function
Discovery teams can screen rapidly in cells, organoids, and imaging systems. But molecular and image-based signals alone may not show whether a candidate produces meaningful function in a living organism, or whether an apparent effect is confounded by sedation, stress, toxicity, impaired physiology, or measurement artifacts.
Human relevance, limited organism context
Cellular and organoid systems provide valuable molecular and tissue-level evidence, but do not capture integrated behavior, circulation, sensory response, recovery, or organism-level tolerability.
Mammalian studies are valuable and scarce
Rodent and other mammalian studies remain essential, but are slower, resource-intensive, and capacity-constrained. They should be reserved for stronger candidates and better-defined questions.
Decision risk in the middle
Teams need earlier evidence about whether a compound produces functional benefit, not only a molecular, fluorescence, or imaging signal.
The opportunity is not to replace mammalian validation. It is to de-risk, rank, and focus it before it starts.